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SpleenThe use of adenovirus serotype 5 (Ad5) vectors in the clinical setting is severely hampered by the profound
liver tropism observed after intravascular delivery coupled with the pronounced inﬂammatory and innate
immune response elicited by these vectors. Liver transduction by circulating Ad5 virions is mediated by a
high-afﬁnity interaction between the capsid hexon protein and blood coagulation factor X (FX), whilst
penton–αvintegrin interactions are thought to contribute to the induction of anti-Ad5 inﬂammatory and in-
nate immune responses. To overcome these limitations, we sought to develop and characterise for the ﬁrst
time novel Ad5 vectors possessing mutations ablating both hexon:FX and penton:integrin interactions. As
expected, intravascular administration of the FX binding-ablated Ad5HVR5*HVR7*E451Q vector (AdT*)
resulted in signiﬁcantly reduced liver transduction in vivo compared to Ad5. In macrophage-depleted mice,
increased spleen uptake of AdT* was accompanied by an elevation in the levels of several inﬂammatory me-
diators. However ablation of the penton RGD motif in the AdT* vector background (AdT*RGE) resulted in a
signiﬁcant 5-fold reduction in spleen uptake and attenuated the antiviral inﬂammatory response. A reduction
in spleen uptake and inﬂammatory activation was also observed in animals after intravascular administration
of Ad5RGE compared to the parental Ad5 vector, with reduced co-localisation of the viral beta-galactosidase
transgene with MAdCAM-1+ sinus-lining endothelial cells. Our detailed assessment of these novel adenovi-
ruses indicates that penton base RGE mutation in combination with FX binding-ablation may be a viable
strategy to attenuate the undesired liver uptake and pro-inﬂammatory responses to Ad5 vectors after intra-
vascular delivery.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Adenoviruses (Ad) are non-enveloped 70–90 nm DNA viruses that
commonly cause a variety of mild illnesses, including gastroenteritis,
conjunctivitis and cystitis [1]. Greater than 56 different human Ad sero-
types have been identiﬁed to date and are classiﬁed into species A–G
[2]. Ad5-based vectors are relatively easy to manipulate, are able to
efﬁciently transduce a wide variety of dividing and quiescent cell
types and it is possible tomanufacture clinical grade virus to high titers.
Consequently, a signiﬁcant proportion of gene therapy clinical trials are
performed using Ad5-based vectors, which are also frequently used for
experimental applications in the laboratory setting [3].n Glasgow Cardiovascular Re-
Sciences, 126 University Place,
1977; fax: +44 141 330 6997.
. Baker).
rights reserved.The three major components of the icosahedral Ad5 capsid are the
trimeric hexon, pentameric penton base and trimeric ﬁbre proteins.
Detailed studies have shown that each capsid component participates
in distinct aspects of the interface between Ad5 virions and the cell
surface. Early in vitro evidence demonstrated that cell tethering by
Ad5 is mediated by an interaction between the ﬁbre knob domain
with the coxsackie and adenovirus receptor (CAR; [4]). Subsequent
binding of αvβ3/αvβ5 integrins to the exposed arginine–glycine–
aspartic acid (RGD) motif in the Ad5 penton base promotes integrin
clustering, resulting in the activation of downstream signalling path-
ways and the induction of cytoskeletal changes required for efﬁcient
virus internalisation and endocytosis ([5,6], [7],[8]). In vivo, however,
several studies have shown that neither CAR nor αv integrin interac-
tions contribute to the profound liver transduction observed after in-
travascular (iv) delivery of Ad5 in rodents and nonhuman primates
[2,9–11]. Indeed, the in vivo localisation of CAR in polarised cells to
intercellular tight junctions renders CAR largely inaccessible to circu-
lating Ad5 virions [12,13]. It is now well established that hepatocyte
Fig. 1. Generation of RGE-mutant Ads. A) Illustration depicting Ad5 vertex, with ribbon
diagrams of penton base pentamer andhexon trimer. B) Schematic illustrating homologous
recombination of RGE-mutated Ad5 penton base shuttle into the pAd5/AdT*-CMVLacZ
backbone. C) Virus particle titers, infectious titers andVP/PFU ratios for all viruses produced.
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action between the Ad5 hexon protein and circulating blood coagula-
tion factor X (FX), which ‘bridges’ the adenovirus capsid to heparan
sulphate proteoglycans (HSPGs) at the cell surface [14–16]. Further-
more, it has been shown that the FX-mediated interaction with
highly-sulphated liver HSPGs involves several positively-charged
residues in the FX serine protease domain, whilst hypervariable
(HVR) regions in the Ad hexon protein bind the FX gamma-
carboxylglutamic acid (Gla) domain [16–19]. Based on this knowl-
edge, concerted efforts to generate an optimised Ad5 vector for
gene therapy applications via this route of administration have been
focused on ablating the nanomolar-afﬁnity FX:Ad5 hexon interaction.
Such studies have yielded a series of novel Ad5 vectors possessing
mutations within the hexon HVR regions responsible for FX binding,
which show markedly reduced liver uptake after iv administration
[15,17,20,21]. However, we have previously shown that the liver-
detargeted, FX binding-ablated Ad5 vector Ad5-HVR5*7*E451Q
(hereafter referred to as AdT*), resulted in increased spleen uptake
accompanied with moderate increases in the inﬂammatory cytokines
interleukin-12 (IL-12), monokine-induced by interferon gamma
(MIG) and 10 kDa interferon gamma-induced protein (IP-10) [22].
The innate immune response to circulating Ad5 virions represents a
signiﬁcant hurdle facing the clinical application of these vectors
[23]. The unfortunate death of a phase I clinical trial participant sever-
al days after intra-arterial infusion of an Ad5-based vector in 1999
further serves to highlight the importance of developing vectors
with limited off-target interactions and improved safety in vivo.
Systemic delivery of Ad5 in mice elicits a marked proinﬂammatory
and cellular immune response both to the viral particle itself and to
its expressed genes [24–28]. Studies indicate that recognition of
viral DNA by immune sensors such as the NLRP3 inﬂammasome in
circulating monocytes and tissue macrophages plays an important
role in the induction of a proinﬂammatory response to Ad5 [29].
Interestingly, it has also been shown that the Ad5 capsid proteins,
speciﬁcally the penton base, may also contribute to the induction of
this proinﬂammatory response by promoting macrophage and
dendritic cell activation in an RGD integrin-dependent manner
[24,30,31]. This observation indicates that mutating the penton base
of FX binding-ablated Ad5 vectors to prevent capsid interactions
with RGD integrins may potentially attenuate the proinﬂammatory
response to these liver-detargeted Ad5 vectors after iv administra-
tion. Mutation of the penton base RGD motif in a FX binding-ablated
vector would also provide further mechanistic evidence for the in-
volvement of penton base-integrin interactions in spleen uptake
after intravascular delivery of AdT*. In this study, we have generated
novel Ad single- and double-mutant vectors containing an RGD-
ablating point mutation in the penton base of control Ad5 or FX
binding-ablated AdT* vectors. We have assessed the effect of these
modiﬁcations on cell attachment and transduction in vitro and have
performed detailed in vivo characterisation of the mutant adenovi-
ruses after iv delivery in macrophage-depleted and control mice.
2. Materials and methods
2.1. Cell lines
The growth requirements of cultured human cell lines HEK293,
SKOV3 and A549 have previously been described in detail [18].
2.2. Adenoviral vector construction
All viruses are based on the AdEasy, E1/E3-deleted human serotype
5 adenovirus (Ad5), which encodes a CMV-LacZ expression cassette
(Strategene, Leicester, UK) (Fig. 1A). Construction of the Ad5-
HVR5*7*E451Q genome (AdT*) has been described previously [17].
A shuttle vector for homologous recombination within the Ad5penton base region was generated by amplifying a 4.6 kB fragment
containing the penton base sequence, ﬂanked by 1.9 kB (left) and
1 kB (right) regions of homology from the Ad5 genome (For: 5′
ATATGACGAGGACGATGAGTACG, Rev: 5′ CGCCGTACACCTCATCATACAC)
(Fig. 1B). An aspartic acid (D) to glutamic acid (E) mutation (5′
CGCGGCGAC 3′->5′CGCGGCGAA 3′) was introduced within the penton
base RGD motif sequence by site-directed mutagenesis of the 1.3 kB
SexA1-AscI fragment of the penton base shuttle vector, using the
Strataclone blunt cloning kit (Stratagene, Leicester, UK) and the primers
For:5′ ATTCGCGGCGAAACCTTTGCCTG and Rev: 5′ GGCAAAGGTTTCG
CCGCGAATGG. The SexA1-AscI RGD-mutated fragment was then
reintroduced into the penton shuttle plasmid by subcloning andﬁnal con-
structs sequenced and veriﬁed using a 3730 DNA analyzer (Applied Bio-
systems, Warrington, UK). The RGE-mutant penton base shuttle plasmid
and the Ad5-CMVLacZ or AdT* genome-containing plasmids were then
linearized using EcoRI and PmeI respectively and homologous recombina-
tion performed in BJ5183 electroporation-competent cells according to
manufacturer's instructions (Stratagene, Leicester, UK). Recombinant ad-
enovirus genomes were veriﬁed by sequencing.
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PacI-digested viral genomes were transfected into HEK293 cells in
a 6-well plate using Lipofectamine2000 according to manufacturer's
instructions (Invitrogen, Paisley, UK). Cells andmedia were recovered
5–10 days post-transfection after viral plaques were observed and
ampliﬁed viruses sequenced (Applied Biosystems, Warrington, UK).
Rescued viruses were propagated in HEK293 cells as previously de-
scribed and puriﬁed by double CsCl gradient centrifugation. Viral par-
ticles were determined by micro bicinchoninic-acid assay (Perbio
Science, Cramlington, UK) according to manufacturer's instructions,
using the formula 1 μg protein=4×109vp [32]. End-point dilution
assays were performed to quantify plaque-forming units (PFU)/ml.
To verify capsid composition, SDS-polyacrylamide gels were loaded
with 5×1010 vp of each adenovirus and stained using the PageSilver
silver staining kit according to manufacturer's instructions (Roche,
Welwyn Garden City, UK).
2.4. Analysis of Ad cell binding in vitro
SKOV3 or A549 cells were plated in 24-well plates at 1×105cells/
well 24 h prior to assay. Cells were gently washed in PBS then incu-
bated in 500 μl serum-free DMEM (SF DMEM) on ice for 30 min.
1×103vp/cell of Ad5, Ad5RGE, AdT* or AdT*RGE in ice-cold SF
DMEM was then added to cells, which were incubated for a further
1 h on ice in the presence or absence of FX at a concentration of
10 μg/ml (Cambridge Bioscience, Cambridge, UK). Cells were then
washed twice with PBS and pelleted by centrifugation at 8000×g.
After lysing cells by freeze-thawing, total cellular DNA was extracted
using the QiaQuick DNeasy extraction kit according to the man-
ufacturer's instructions (Qiagen, Crawley, UK). Vector genomes
were detected in 100 ng total DNA by SYBR green quantitative poly-
merase reaction (qPCR) on an ABI Prism 7700 sequence detection
system (Applied Biosystems, Warrington, UK) using primers di-
rected against an unmutated portion of the Ad5 hexon gene (For
5′-CGCGGTGCGGCTGGTG-3′and Rev 5′-TGGCGCATCCCATTCTCC-3′).
Data are expressed as vp/100 ng DNA.
2.5. Analysis of Ad transduction in vitro
SKOV3 or A549 cells were plated out in 96-well plates at
2×104cells/well 24 h prior to infection. Cells were gently washed
with PBS then incubated with 1×103vp/cell Ad5, AdT*, Ad5RGE or
AdT*RGE in 100 μl SFDMEM for 3 h at 37 °C, in the presence or ab-
sence of FX at a concentration of 10 μg/ml (Cambridge Bioscience,
Cambridge, UK). Infection media were removed from cells, which
were washed gently with PBS prior to addition of 200 μl full medium
and incubation at 37 °C for 48 h. Cells were harvested by lysing in
100 μl 0.2% Triton-X-100/PBS. β-galactosidase was quantiﬁed using
Tropix Galacto-light Plus (Applied Biosystems, Warrington, UK) and
visualised by ﬁxing cells in 2% paraformaldehyde for 10 min at
room temperature followed by staining in 5-bromo-4-chloro-3-
indolyl-ß-D-galactosidase (X-Gal) staining solution for 3 h at 37 °C
[0.1 M pH7.3 phosphate buffer, 2 mM MgCl2, 5 mM K3F3(CN)6,
5 mM K4Fe(CN6)6, and 1 mg/ml X-Gal]. β-galactosidase activity was
quantitated using a Wallac VICTOR2 (PerkinElmer Life and Analytical
Sciences, Boston MA) and normalised to total protein concentrations.
Protein concentrations were measured by BCA as per manufacturer's
instructions. Data are expressed as Relative Light Units (RLU)/mg
protein.
2.6. Adenovirus delivery in vivo
All animal experiments were approved by the UK Home Ofﬁce.
Male MF1 outbred mice (Harlan, UK) aged between 8 and 10 weeks
(weight approx. 35 g) and housed in secure barrier facilities wereused for all in vivo experiments. Macrophage depletion was carried
out by iv administration of 200 μl clodronate-encapsulated liposomes
(clodronate liposomes; www.clodronateliposomes.org) 48 h prior to
Ad administration. For in vivo transduction studies, 1×1011vp Ad
was administered by iv injection 48 h after PBS (−CD) or
macrophage-depletion (+CD). Mice were sacriﬁced and perfused
with PBS 48 h post-injection. β-galactosidase transgene expression
in tissue was assayed using a β-galactosidase enzyme-linked immu-
nosorbent assay (ELISA) kit (Roche, Welwyn Garden City, UK)
according to manufacturer's instructions, and normalised to total pro-
tein content assayed by BCA as described previously. Liver lobes and
spleens that had been ﬁxed in 2% paraformaldehyde (PFA) for 16 h
at 4 °C were stained for β-galactosidase activity in X-Gal staining so-
lution (described above) at 37 °C overnight.
2.7. Immunohistochemistry in liver and spleen
Tissues were embedded in Optimal Cutting Temperature (OCT)
medium-containing cryomolds (Tissue-Tek, U.S.A.) and frozen at
−80 °C immediately after necropsy. To assess the effect of macro-
phage depletion on deﬁned cell populations, spleen (6 μm) or liver
(4 μm) sections from untreated (−CD) or clodronate liposome-
treated (+CD) mice were analysed by immunohistochemistry using
antibodies directed against Kupffer cell marker F4/80 and spleen
cell markers MARCO, Moma-1 (also known as CD169), B220,
MadCAM-1 and ER-TR7, performed exactly as described previously
[22]. Co-localisation of viral transgene expression (β-galactosidase)
was assessed by staining tissue sections with a rabbit polyclonal
anti-β-galactosidase antibody (MP Biomedicals LLC) in combination
with F4/80 (liver Kupffer cells), the endothelial marker CD31 (liver),
MARCO, Moma-1, B220, MAdCAM-1 or ER-TR7, as previously
reported [22]. Immunoﬂuorescence images were acquired on an
Olympus BX60 ﬂuorescence microscope using CellM image analysis
software (Olympus, Southend, UK) or on a Zeiss LSM510 confocal im-
aging system using LSM image acquisition software (Carl Zeiss,
Welwyn Garden City, UK).
2.8. Cytokine and chemokine analysis
Ad5, Ad5RGE, AdT*, AdT*RGE (1×1011vp) was administered by iv
injection to untreated (−CD) or macrophage-depleted groups
(+CD). Blood was extracted by venesection and collection in capil-
lary tubes 6 h after virus administration. Blood from PBS controls
(−/+CD) was also collected at this timepoint. Serum was prepared
by allowing blood to coagulate for 30 min at room temperature then
centrifuging at 10,000×rpm for 15 min. Cytokine and chemokine
analysis of 6 h sera was performed using a mouse cytokine 20-plex
luminex panel according to manufacturer's instructions (Invitrogen,
Paisley, UK), quantifying levels of basic ﬁbroblast growth factor
(bFGF), granulocyte macrophage colony-stimulating factor (GM-
CSF), interferon-gamma (IFN-γ), interleukin (IL) 1α, IL-1ß, IL-2,
IL-4, IL-5, IL-6, IL-10, IL-12(p40/p70), IL-13, IL-17, IFN-induced pro-
tein (IP10), keratinocyte-derived cytokine (KC), monocyte chemo-
attractant protein (MCP-1), monokine induced by gamma interferon
(MIG), macrophage inﬂammatory protein-1alpha (MIP-1α), tumour
necrosis factor-alpha (TNF-α) and vascular endothelial growth factor
(VEGF). Data were analysed using Bio-Plex manager software with
5PL curve ﬁtting. Values are presented as pg/ml after correction for
the background levels from animals in the PBS groups (+/−CD).
3. Results
Two key concerns limiting the clinical application of Ad5 vectors
for gene therapy are the profound liver uptake and acute inﬂammato-
ry activation observed after intravascular delivery. We and others
have previously shown that mutation of the HVR regions within the
Fig. 2. In vitro cell binding and transduction of RGE-mutant Ads. A) Binding of 1000 vp/cell
of Ad5, Ad5RGE, AdT* and AdT*RGE to SKOV3 human ovarian carcinoma or A549 human
lung carcinoma cells at 4 °C in the presence or absence of a physiological concentration of
FX (10 μg/ml). B) Transduction of SKOV3 or A549 cells by Ad5, Ad5RGE, AdT* or AdT*RGE
in the presence or absence of 10 μg/ml FX after exposure to cells for 3 h at 37 °C. Cell trans-
ductionwas assessed byβ-galactosidase assay and lacZ staining 48 h post-infection. n=5,
**=pb0.01 compared to –FX control.
397A.C. Bradshaw et al. / Journal of Controlled Release 164 (2012) 394–402hexon protein results in ablation of Ad5 binding to FX, signiﬁcantly at-
tenuating hepatocyte transduction [15–17,22]. However, FX binding-
ablated Ad5 vectors are hampered by increased spleen uptake
after IV administration in macrophage-depleted animals, accompa-
nied by a moderate increase in circulating inﬂammatory cytokine
levels compared with the unmodiﬁed Ad5 vector [17]. The underlying
mechanism has yet to be elucidated, although there is evidence
to suggest that interactions between the penton base RGD motif
and αv integrins may be involved [22,24,30]. Thus the goal of the
present study was to generate and perform detailed in vitro and in
vivo characterisation of novel single and dual mutant Ad5 vectors
containing penton base RGE mutations and hexon mutations ablating
FX binding.
3.1. Construction and characterisation of Ad5RGE and AdT*RGE vectors
Two novel Ad5 vectors based on Ad5 and the FX binding-ablated
Ad5 vector AdT* were constructed to assess the role of the penton
RGD>RGE motif mutation alone and in combination with FX
binding-ablation.
Ad5RGE and AdT*RGE were generated by homologous recombina-
tion of a shuttle plasmid containing an RGE-mutated penton base into
the Ad5 and AdT* adenovirus backbones respectively, as described in
the Materials and methods (Fig. 1A+B). To characterise capsid pro-
tein content of mutant and parental vectors, 5×1010 virus particles
of each vector were separated by SDS-PAGE and analysed by silver
stain (Fig. S1). Silver stain proﬁles of all viruses were similar
(Fig. S1), indicating that the modiﬁcations had not disrupted the
structural integrity of the particles. End-point dilution assays to quan-
tify plaque-forming units (PFU) were also performed and VP/PFU ra-
tios calculated (Fig. 1C). Importantly, VP/PFU ratios for all viruses
were in the same range, allowing us to directly compare the in vitro
and in vivo characteristics of the four vectors.
3.2. Similar binding and transduction of human cell lines by mutant Ads
To assess whether mutation of the penton RGD motif affects in
vitro binding and transduction of unmodiﬁed or FX binding-ablated
Ad, cell attachment and transduction assays were performed in
SKOV3 ovarian carcinoma or A549 lung carcinoma cells in the pres-
ence or absence of physiological concentrations of FX. Unlike SKOV3
cells, A549 cells express high levels of the primary Ad5 attachment
receptor, CAR [33,34]. A signiﬁcant increase in binding (Fig. 2A) and
transduction (Fig. 2B) of both SKOV3 and A549 cells was observed
with Ad5 and Ad5RGE viruses in the presence of FX (p>0.01), consis-
tent with previous studies showing that penton base:integrin interac-
tions are not required for FX-mediated transduction [18,22]. As
expected, no FX-mediated increase in binding (Fig. 2A) and transduc-
tion (Fig. 2B) of either cell type was observed with AdT* or AdT*RGE.
Interestingly, all RGE-mutant viruses retained the ability to transduce
both cell types at relatively low levels in the absence of FX, indicating
that alternate internalisation pathways may mediate uptake of Ad5
under these conditions.
3.3. Modiﬁed biodistribution of RGE-mutant Ads after iv delivery
To characterise the effect of the RGE mutation on the in vivo bio-
distribution of unmodiﬁed and FX binding-ablated Ad5 vectors, we
studied the effect of high-dose virus administration in macrophage-
depleted and non macrophage-depleted mice. The viral genome con-
tent (Fig. 3A) of organs 48 h after iv administration of 1×1011 vp of
Ad5, Ad5RGE, AdT* or AdT*RGE was quantiﬁed, while viral transgene
expression (Fig. 3B) was assessed by β-galactosidase ELISA (Fig. 4A
and B). In both macrophage-depleted (+CD) and non-macrophage-
depleted mice (−CD), high levels of liver genome accumulation and
transduction were observed after iv administration of Ad5 andAd5RGE (Figs. 3A/B and 4), conﬁrming the redundancy of penton
base-integrin interactions for liver uptake in MF1 mice. Conversely,
FX binding-ablated vectors mediated signiﬁcantly reduced levels of
liver genome accumulation and transduction in both macrophage-
depleted and non-macrophage-depleted animals (pb0.01; Fig. 3). In
non macrophage-depleted AdT* and AdT*RGE animals, vector ge-
nome accumulation and β-galactosidase expression were primarily
localised to the spleen and lung (Fig. 3; −CD). Low levels of lung
transduction and genome accumulation were also observed in non-
macrophage-depleted Ad5 and Ad5RGE animals (Fig. 3; −CD).
Interestingly, a signiﬁcant, 5-fold reduction in spleen viral genome
accumulation and transduction was observed after Ad5RGE adminis-
tration to non-macrophage-depleted animals compared to the paren-
tal Ad5 vector (Fig. 3, −CD; pb0.05). In the spleen, we observed
a similar reduction in viral genome accumulation and transduction
in macrophage-depleted AdT*RGE animals compared to animals
administered the parental AdT* vector (Fig. 3, +CD; pb0.01). There
was no signiﬁcant reduction in spleen transduction of macrophage-
depleted animals by Ad5RGE compared to the parental Ad5 vector
(Figs. 3 and 4; +CD). In macrophage-depleted animals, signiﬁcantly
Fig. 3. Viral genome content and transduction proﬁles of tissues frommice injected with
parental and RGE-mutant Ads. Viral genome content was assessed by qPCR analysis of
DNA extracted from tissues, using primers speciﬁc to an unmutated portion of the adeno-
virus hexon gene. β-galactosidase expression was quantiﬁed by ELISA and normalised to
total protein content assayed by BCA. A) Viral genome content of the liver, spleen, lung,
heart and kidneys from non macrophage-depleted (−CD) and macrophage-depleted
(+CD) mice 48 h after iv administration of 1x1011 vp of Ad5, Ad5RGE, AdT* or AdT*RGE.
B) β-galactosidase expression in the liver, spleen, lung, heart and kidneys from non
macrophage-depleted (−CD) andmacrophage-depleted (+CD)mice 48 h after iv admin-
istration of 1x1011 vp of Ad5, Ad5RGE, AdT* or AdT*RGE. n=5/group, values expressed as
mean+/−SEM. *=pb0.05, **=pb0.01 compared to Ad5. †=pb0.05, ‡b=bpb0.01
compared to parental vector (AdT*).
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non-macrophage-depleted AdT* animals, consistent with previous
studies (Figs. 3 and 4, pb0.01). IV administration of Ad vectors toFig. 4. β-Galactosidase staining of livers and spleens frommice injectedwith parental and
RGE-mutant adenoviruses. X-Gal staining of the liver lobes (A) and spleens (B) 48 h after
intravascular administration of 1x1011 vp Ad5, Ad5RGE, AdT* or AdT*RGE.macrophage-depleted mice led to minimal levels of lung, heart and
kidney viral genome accumulation and transduction (Fig. 3; +CD).
3.4. Absence of hepatocyte transduction after IV delivery of FX
binding-ablated Ads
To characterise liver transduction by RGE-mutant Ads after iv ad-
ministration, frozen liver sections from macrophage-depleted and
non-macrophage-depleted mice administered 1×1011 vp of Ad5,
Ad5RGE, AdT* or AdT*RGE were analysed by immunohistochemistry.
Clodronate liposome pretreatment resulted in signiﬁcant depletion of
F4/80+ liver Kupffer cells (Supplementary Fig. S2; upper panel).
Similar, intense staining for β-galactosidase was observed in liver
sections from macrophage-depleted (+CD) and non-macrophage-
depleted (−CD) mice administered Ad5 and Ad5RGE, with transgene
expression localising primarily to hepatocytes (Fig. 5). A moderate in-
crease in β-galactosidase staining was seen in liver sections from
macrophage-depleted (+CD) Ad5 and Ad5RGE animals compared to
non-macrophage-depleted counterparts (Fig. 5). No β-galactosidase
expression was observed in liver sections from mice administered
AdT* or AdT*RGE (Fig. 5).
3.5. Viruses interact with multiple cell types in the spleen
In order to identify the cell types in the spleen expressing the
β-galactosidase transgene 48 h following iv delivery of 1×1011 vp
Ad5, Ad5RGE, AdT* or AdT*RGE, we performed co-localisation by
immunohistochemistry (Figs. 6 and 7). The distribution of transgene
expression in non macrophage-depleted animals (−CD) was largely
localised to the marginal zone (MZ), although numerous β-Gal+
cells were also detectable within the red pulp (RP) region (Figs. 6
and 7A). The MZ contains specialised macrophages, MARCO+ scav-
enging macrophages and Moma-1 (CD169+) marginal metallophilic
macrophages (MMM), which previously have been shown to trapFig. 5. mmunohistochemical analysis of β-galactosidase expression in liver sections.
Immunohistochemical analysis of 4 μm frozen liver sections from the control or
macrophage-depleted mice injected with 1x1011 vp Ad5, Ad5RGE, AdT* or AdT*RGE
viruses 48 h prior to sacriﬁce. Sections were stained for β-galactosidase (green) and
the macrophage marker F4/80 or the endothelial cell marker CD31. Merged images
of liver sections from the control or macrophage-depleted mice injected with 1x1011
vp of Ad5, Ad5RGE, AdT* or AdT*RGE and stained for s-galactosidase (green) and
F4/80 or CD31 (red).
Fig. 6. Immunohistochemical analysis of β-galactosidase expression and macrophage
markers in the spleens of non-macrophage-depleted animals. Immunohistochemical
analysis of 6 μm spleen sections from control (−CD) mice injected iv with 1x1011 vp
Ad5, Ad5RGE, AdT* or AdT*RGE 48 h prior to sacriﬁce. Sections were stained for viral
transgene, β-galactosidase (green) and spleen macrophage cell markers MARCO and
Moma-1. Note: β-galactosidase is abbreviated to β-Gal in ﬁgure. Images shown were
captured using a 10× or 40× objective and are representative of multiple ﬁelds of
view. Regions of interest are highlighted by a box and magniﬁed in the corresponding
panel below.
Fig. 7. Immunohistochemical analysis of β-galactosidase expression and in the spleens of
control (A) and macrophage-depleted animals (B). Immunohistochemical analysis of 6 μm
spleen sections from control (−CD) or macrophage-depleted (+CD) mice injected iv with
1x1011 vp Ad5, Ad5RGE, AdT* or AdT*RGE 48 h prior to sacriﬁce. Sections were stained for
viral transgene, β-galactosidase (green) and spleen cell markers B220, MAdCAM-1 or
ERTR7 (red).Note:β-galactosidase is abbreviated toβ-Gal inﬁgure. Images shownwere cap-
tured using a 10× or 40× objective and are representative of multiple ﬁelds of view. Regions
of interest are highlighted by a box and magniﬁed in the corresponding panel below.
399A.C. Bradshaw et al. / Journal of Controlled Release 164 (2012) 394–402Ad5 particles at early time-points post-injection [24]. We detected
similar levels of Ad5, Ad5RGE, AdT and AdT*RGE viral transgene ex-
pression in MARCO+ andMoma-1+ cells (Fig. 6). We failed to detect
any co-localisation with MARCO+/Moma-1+ cell in animals pre-
treated with clodronate liposomes, as these particular macrophage
populations are completely eliminated by the treatment regime
([22] and Supplementary Fig.S2). We detected B220+ transgene-
expressing cells extending into the boundaries of the white pulp
(WP) and some isolated B220+/β-Gal+ cells were also identiﬁed
within the centre of the WP (Fig. 7A). We have shown previously that
virus transgene expression can be detected within MAdCAM-1+
sinus-lining endothelial cells and ER-TR7+ reticular ﬁbroblasts and
ﬁbres [22]. In this study, we found that Ad5 and to a lesser degree,
AdT*, co-localised with MAdCAM-1+ endothelial cells (Fig. 7A).
Conversely, β-galactosidase expression from RGE-modiﬁed vectors,
Ad5RGE and AdT*RGE, were detected in close proximity to MAdCAM-
1+ cells, but did not co-localise to a signiﬁcant degree. All vectors
appeared to associate to the same degree with ER-TR7+ reticular ﬁbro-
blasts (Fig. 7A).
We have previously shown that MAdCAM-1+ and ER-TR7+ cells
remain unaffected by clodronate pre-treatment ([22] and Supple-
mentary Fig. S2). In macrophage-depleted animals (+CD), the distri-
bution of transgene expression was largely localised to the MZ,
although β-galactosidase+ cells were also detected within the
white pulp (WP). In agreement with quantitation of genomes, levels
of transgene expression in AdT* groups were substantially higher
than other treatment groups (~3–5 fold higher; pb0.01).
We detected co-localisation of β-galactosidase with B220+ cells,
again at the WP boundaries and within the germinal centres. We
also detected AdT* transgene expression in MAdCAM-1+ and ER-
TR7+ cells, as previously reported [22]. Similar to untreated (−CD)
animals, co-localisation of β-galactosidase with MAdCAM-1+ endo-
thelial cells was limited to Ad5 and AdT*-treated groups and was
not detected in Ad5RGE or AdT*RGE groups. All viruses were found
to be associated with ER-TR7+ reticular ﬁbroblasts (Fig. 7), though
this was more clearly evident for AdT* due to increased amounts of
virus in the spleens of these animals.3.6. Altered inﬂammatory proﬁles in response to RGE-mutant Ads
Several studies have shown that iv delivery of Ad5 vectors to naïve
mice triggers a robust inﬂammatory and cellular immune response,
with elevated levels of serum cytokines and chemokines observed
for several hours after administration [24–27,30,35]. To identify the
effect of the penton base RGE mutation on the systemic toxicity asso-
ciated with iv delivery of both control (Ad5) and FX binding-ablated
(AdT*) vectors, serum was obtained from all groups of mice 6 h after
administration of Ad5, Ad5RGE, AdT* or AdT*RGE (Fig. 8). In non-
macrophage-depleted mice (−CD), Ad5 induced signiﬁcantly higher
levels of IL-12, IL-5, IL-1α, IL-1β, IP-10 and MCP-1 than any of the
other vectors (pb0.05 or pb0.01). Macrophage depletion markedly
attenuated this effect, with only interferon-gamma (IFN-γ), IL-5,
IL-1α, IP-10 and MCP-1 present at detectable (albeit signiﬁcantly
reduced) levels in Ad5 animals. Conversely, in macrophage-depleted
animals AdT* induced signiﬁcantly higher levels of IFN-γ, IL-12, IL-5,
IL-6 and IL-1β than Ad5 vectors (pb0.05; Fig. 8). Interestingly, muta-
tion of the Ad5 penton base RGDmotif signiﬁcantly attenuated the in-
crease in IL-12, IL-5, IL-6, IL-1α, IL-1β, IP-10 and MCP-1 observed in
non-macrophage-depleted Ad5 animals. Similarly, signiﬁcantly re-
duced levels of IL-12, IL-6 and IL-1α were observed in non-
macrophage-depleted AdT*RGE animals compared to animals receiv-
ing the parental AdT* vector. A signiﬁcant reduction in IL-12, IP-10,
IFN-γ and MCP-1 was also observed in macrophage-depleted animals
Fig. 7 (continued).
Fig. 8. Chemokine/cytokine analysis of sera from mice 6h after administration of RGE-
mutant Ads. Chemokines and cytokines in sera from mice 6 h after intravascular ad-
ministration of 1x1011 vp Ad5, Ad5RGE, AdT* or AdT*RGE were quantitated using a
mouse 20-plex Luminex kit according to manufacturer’s instructions. Values expressed
as mean+/-SEM. *=pb0.05, **=pb0.01 compared to parental vector (Ad5 or AdT*).
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together, these data suggest that mutation of the penton RGD motif
in both the Ad5 and AdT* background signiﬁcantly attenuates the
Ad-mediated induction of selected inﬂammatory factors after iv
administration.
4. Discussion
The goal of the present study was to generate and characterise
penton base RGE-mutated Ad5 vectors on both control and FX
binding-ablated backgrounds, in order to assess the contribution of
penton base:integrin interactions to the increased spleen uptake
and inﬂammatory responses observed after intravascular administra-
tion of FX binding-ablated Ad vectors.
All mutant adenoviruses were successfully grown in HEK293 cells,
yielding relatively high particle titers and similar VP/PFU ratios after
two-step CsCl ultracentrifugation. Silver stain analysis showed almost
identical capsid composition proﬁles for Ad5RGE and AdT*RGE virus-
es and their parental Ad5 and AdT* vectors, indicating that single or
dual ablation of FX- and RGD-integrin binding had no signiﬁcant ef-
fect on virion assembly and propagation. RGE-mutant adenoviruses
also retained the ability to bind and transduce CARhigh A549 and
CARlow SKOV3 cells in the absence of FX. Although the classical
model of Ad5 entry indicates that integrins are required for virus
internalisation and endocytosis, studies on the canine adenovirus
CAV-2 (which does not possess a penton base RGD motif) have
shown co-localisation of CAR with ﬂuorescently-labeled CAV-2 parti-
cles in axonal transport vesicles [36]. Ad5RGE and AdT*RGE may
therefore use alternate internalisation pathways to gain entry to
cells in the absence of a functional penton base RGD motif. In the
presence of FX, no increase in AdT* or AdT*RGE cell binding or trans-
duction was observed, consistent with previous studies on the AdT*
vector [17]. Similarly, high levels of FX-mediated binding andtransduction of A549 and SKOV3 cells by Ad5 and Ad5RGE vectors
was observed, in accordance with previous data showing that abla-
tion of the penton base RGD motif does not affect FX-mediated bind-
ing and transduction [18]. Importantly, these results indicate that
mutation of the penton RGDmotif on a FX binding-ablated AdT* back-
ground does not signiﬁcantly compromise the capsid composition or
infectivity of this vector.
Assessment of virus biodistribution after iv delivery of Ad5,
Ad5RGE, AdT* or AdT*RGE to macrophage-depleted and non-
macrophage depleted control mice revealed similarly high levels of
liver transduction by Ad5 and Ad5RGE, conﬁrming the redundancy
of the penton RGD motif for FX-mediated hepatocyte uptake in vivo.
Interestingly, a 5-fold reduction in spleen uptake of Ad5RGE com-
pared to the parental Ad5 vector was observed in non-macrophage-
depleted animals. Immunohistochemical analysis of spleen sections
from these animals showed that although both Ad5 and Ad5RGE
transduced marginal zone cell populations, signiﬁcant transgene
colocalisation with MAdCAM-1+ sinus-lining endothelial cells was
only observed in Ad5-administered animals. Similarly, a comparable
6-fold reduction in spleen uptake and transduction was accompanied
by decreased colocalisation of the β-galactosidase transgene with
MAdCAM-1 in spleen sections from macrophage-depleted AdT*RGE
animals compared to AdT* counterparts. Previous studies indicate
that activation of sinusoidal endothelial cells in the liver after iv deliv-
ery of Ad5 is signiﬁcantly attenuated by deletion of the penton base
RGD motif [37,38], whilst in vitro transduction of human pulmonary
artery, coronary artery and umbilical vein endothelial cells can be sig-
niﬁcantly increased by insertion of an RGD motif into the Ad5 ﬁbre
knob domain [39]. Taken together, these data suggest that uptake of
401A.C. Bradshaw et al. / Journal of Controlled Release 164 (2012) 394–402Ad5 vectors by sinus-lining endothelial cells in the spleen may be
mediated by an interaction between the penton base RGD motif and
cellular integrins. Further detailed in vivo studies on the role of liver
and spleen endothelial cells at early timepoints after intravascular
delivery of Ad5 are required to conﬁrm this hypothesis. Moreover,
as ablation of the penton base RGD motif did not entirely eliminate
spleen uptake after intravascular delivery of Ad5 or AdT* vectors,
further investigations on the alternate mechanisms underlying trans-
duction of this organ are also essential.
Although a signiﬁcant component of the anti-Ad5 inﬂammatory
and innate immune response is due to the intracellular recognition
of viral DNA and RNA sequences by immune sensors such as the
NLRP3 inﬂammasome [29,40] and cytosolic defensins [41], studies
have also identiﬁed a role for the capsid penton base protein in RGD
integrin-mediated Ad5 uptake and activation of immune cell types,
including bone marrow macrophages [30], bone marrow-derived
dendritic cells [42] and splenic marginal zone macrophages [24].
RGD-mediated Ad5 uptake by these cells after intravascular delivery
is associated with the upregulation of numerous inﬂammatory cyto-
kines and chemokines, including IFN-γ, IP-10, TNF-α and the MIP-1
proteins [24,30]. Interestingly, transduction of human umbilical vein
endothelial cells by a penton base RGD-ablated Ad5 vector is associat-
ed with signiﬁcantly reduced induction of several chemokines, in-
cluding IP-10 [37]. Di Paolo et al.'s elegant dissection of the IL-1α-
mediated, toll-like receptor and inﬂammasome-independent innate
immune response elicited by interactions between Ad5 and cell sur-
face receptors indicate that spleen macrophage populations may be
an important source of circulating inﬂammatory cytokines at early
timepoints after intravascular administration of Ad5 [24]. The spleen
was also found to be an important site of inﬂammatory cytokine and
chemokine expression in an earlier study investigating early inﬂam-
matory activation after iv delivery of ﬁbre-mutated Ad5 vectors
[43]. In accordance with these studies, the decreased spleen uptake
of Ad5RGE compared to Ad5 after intravascular delivery to non-
macrophage-depleted animals was accompanied by a signiﬁcant
decrease in the levels of several inﬂammatory mediators, including
IL-12, IL-6, IP-10 and MCP-1. Macrophage depletion also resulted in
a general reduction in circulating inﬂammatory cytokines and
chemokines. Interestingly, the increased spleen uptake of AdT* after
intravascular administration to macrophage-depleted mice was ac-
companied by signiﬁcantly elevated levels of IFN-γ, IL-12, IL-6 and
IL-1β, indicating that cells unaffected by clodronate liposome-
mediated macrophage depletion may be an important source of cyto-
kines and chemokines in these animals. As stated previously, ablation
of the penton RGD motif in AdT* attenuated spleen uptake and re-
duced levels of circulating inﬂammatory factors.
Taken together, these results provide valuable information indi-
cating that novel adenoviral vectors with dual mutation of the penton
base RGD motif and hexon:FX-interacting residues constitute a viable
and attractive platform for intravascular gene therapy applications.
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